MedTrace Logo

Efavirenz 400mg in Treatment-naïve Chinese HIV-infected Patients

NCT04596488 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2020-10-23

No results posted yet for this study

Summary

Evaluating the efficacy, pharmacodynamics, and safety of Efavirenz 400mg in treatment-naïve Chinese HIV-infected patients.

Conditions

Interventions

DRUG

Efavirenz 400mg

HIV-infected patients were treated with efavirenz 400mg combined with tenofovir 300mg and lamivudine 300mg.

Sponsors & Collaborators

  • National Key Technologies R&D Program for the 13th Five-year Plan

    collaborator UNKNOWN

  • National Key Technologies R&D Program for the 12th Five-year Plan

    collaborator UNKNOWN

  • CAMS Initiative for Innovative Medicine

    collaborator UNKNOWN

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Taisheng Li, MD, PhD · Peking Union Medical College Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2018-12-30
Completion
2019-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04596488 on ClinicalTrials.gov